Background The pathophysiology of multiple sclerosis disease progression remains
undetermined. The aim of this study was to identify differences in plasma proteome during …

Background: The lack of effective serum and cerebrospinal fluid (CSF) biomarkers remains a
barrier to early diagnosis and treatment of multiple sclerosis (MS). The study is to identify the …

Multiple sclerosis (MS) is associated with chronic degeneration of the central nervous
system and may cause permanent neurological problems and considerable disability. While …

The multifaceted nature of multiple sclerosis requires quantitative biomarkers that can
provide insights related to diverse physiological pathways. To this end, proteomic analysis of …

Objectives The aim of the present study was to identify proteins in cerebrospinal fluid (CSF)
with different abundance between patients with relapsing‐remitting multiple sclerosis …

The diagnosis of multiple sclerosis (MS) is challenging for the lack of a specific diagnostic
test. Recent researches in quantitative proteomics, however, offer new opportunities for …

Early diagnosis and treatment of multiple sclerosis (MS) in the initial stages of the disease
can significantly retard its progression. The aim of the present study was to identify changes …

Background A quantitative measurement of serum proteome biomarkers that would
associate with disease progression endpoints can provide risk stratification for persons with …

Background and purpose Susceptibility to multiple sclerosis (MS) is determined by
environmental and genetic factors, but the cause remains unknown. Changes to the …

Objective Here, we aimed to identify protein biomarkers that could rapidly and accurately
diagnose multiple sclerosis (MS) using a highly sensitive proteomic immunoassay. Methods …